This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

Exploring equitable treatment options for pediatric patients with sickle cell disease

Sickle cell disease
Credit: National Institutes of Health

Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.

A new study led by Yale Cancer Center researchers at Yale School of Medicine for the first time analyzed the cost-effectiveness of allotransplantation therapy and to help determine equitable treatment options for this historically marginalized pediatric patient population in the United States. First author George Goshua, MD, a member of Yale Cancer Center, will present the findings at the American of Society for Hematology (ASH) Annual Meeting on December 10.

The study used an incremental cost-effectiveness ratio (ICER) to evaluate cost-effectiveness of each therapy. Allotransplantation had an ICER of $138,000 per quality-adjusted life-year (QALY), while gene therapy had an ICER of $253,000.

"While these appear to be expensive, and they are, pursuing allotransplantation or gene therapy both meet distributional equity standards in the United States," said Goshua, who is an assistant professor of medicine (Hematology) at Yale School of Medicine.

Researchers emphasize the importance of considering equity in for pediatric SCD treatment. "We hope to continue to provide more equity and value-informed transparent benchmarks for stakeholders making crucial funding decisions, and also that other groups join us in doing so," said Goshua.

More information: George Goshua et al, Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States. ash.confex.com/ash/2023/webpro … ram/Paper191072.html

Provided by Yale University
Citation: Exploring equitable treatment options for pediatric patients with sickle cell disease (2023, December 11) retrieved 16 June 2024 from https://medicalxpress.com/news/2023-12-exploring-equitable-treatment-options-pediatric.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Treatment cost analysis highlights systemic health inequities faced by persons with sickle cell disease

0 shares

Feedback to editors